Immune-mediated diarrhea and colitis with normal biochemical, endoscopic and histologic findings: a retrospective study.

ABSTRACT:

Background

Immune-mediated diarrhea and colitis (IMDC) due to checkpoint inhibition infrequently presents with normal stool biomarkers and no endoscopic or histologic evidence of inflammation. Little is known about the treatment needs and outcomes of this subset of patients. We aimed to describe this entity and clarify the role of immunosuppressive treatments in its management.

Method

This was a single-center, retrospective study of patients treated with immune checkpoint inhibitors who developed clinical symptoms of IMDC, with no evidence of inflammation based on fecal calprotectin or endoscopic/histologic evaluation, between January 2010 and February 2024.

Results

Of 1151 patients with IMDC, 131 (11.4%) had no evidence of inflammation. These patients more frequently

SUBMITTER: Shatila M 

PROVIDER: S-EPMC12850695 | biostudies-literature | 2026 Jan-Feb

REPOSITORIES: biostudies-literature